Emerging Targeted Therapies for Castration-Resistant Prostate Cancer

Until recently, few therapeutic options were available for patients with castration-resistant prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit (sipuleucel-T, cabazitaxel, abiraterone, and denosumab) have been approved in this setting, and to-date several other agent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Adamo, Vincenzo, Noto, Laura, Franchina, Tindara, Chiofalo, Giuseppe, Picciotto, Maria, Toscano, Giuseppe, Caristi, Nicola
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Research Foundation 2012
Matèries:
Endocrinology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3364443/
https://ncbi.nlm.nih.gov/pubmed/22666217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2012.00073
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars